Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Gross Profit (2016 - 2023)

Perspective Therapeutics' Gross Profit history spans 14 years, with the latest figure at -$39000.0 for Q4 2023.

  • For Q4 2023, Gross Profit changed N/A year-over-year to -$39000.0; the TTM value through Dec 2023 reached $1.4 million, down 66.04%, while the annual FY2023 figure was $1.4 million, N/A changed from the prior year.
  • Gross Profit for Q4 2023 was -$39000.0 at Perspective Therapeutics, down from $738000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $2.4 million in Q2 2022 and bottomed at -$39000.0 in Q4 2023.
  • The 5-year median for Gross Profit is $1.1 million (2019), against an average of $1.0 million.
  • The largest annual shift saw Gross Profit surged 135.88% in 2019 before it plummeted 89.52% in 2023.
  • A 5-year view of Gross Profit shows it stood at $1.1 million in 2019, then grew by 5.04% to $1.2 million in 2020, then increased by 4.54% to $1.2 million in 2021, then tumbled by 66.07% to $414000.0 in 2022, then crashed by 109.42% to -$39000.0 in 2023.
  • Per Business Quant, the three most recent readings for CATX's Gross Profit are -$39000.0 (Q4 2023), $738000.0 (Q3 2023), and $248000.0 (Q2 2023).